SCHEMBL2597345

SCHEMBL2597345

COc1cc(C=O)c(F)c(OCCO)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
ERN1 O75460 10/20 0.41
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 2/20 0.39
TRIM24 O15164 1/20 0.37
TYR P14679 1/20 0.37
TRIM33 Q9UPN9 1/20 0.37
BRD4 O60885 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TUBB1 Q9H4B7 1/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1618936 0.90 ALDH1A1 (0.42) ALDH1A1ERN1KDM4ERAB9AMAPT
SCHEMBL2700325 0.87 ALDH1A1 (0.42) ALDH1A1ERN1KDM4ERAB9AMAPT
SCHEMBL14726040 0.82 ERN1 (0.45) ALDH1A1ERN1KDM4EMAPTTUBB1
SCHEMBL1619656 0.81 ALDH1A1 (0.56) ALDH1A1ERN1KDM4EMAPTTRIM24
SCHEMBL9155251 0.80 KDM4E (0.56) ALDH1A1ERN1KDM4ERAB9AMAPT
SCHEMBL5882846 0.79 ALDH1A1 (0.65) ALDH1A1ERN1KDM4ERAB9AMAPT
SCHEMBL13095974 0.78 BRD4 (0.42) ALDH1A1MAPTBRD4TUBB1MEN1
SCHEMBL2700219 0.77 ERN1 (0.39) ALDH1A1ERN1KDM4ERAB9AMAPT
SCHEMBL5285862 0.76 ERN1 (0.51) ERN1KDM4ERAB9AMAPTTUBB1
SCHEMBL13085607 0.75 MEN1 (0.40) ALDH1A1BRD4L3MBTL1TUBB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571862-B1 PRODRUG OF TRIAZOLONE COMPOUND EISAI R&D MAN CO LTD (JP) 2014-04-16 EP disclosed
EP-2571862-B1 PRODRUG OF TRIAZOLONE COMPOUND EISAI R&D MAN CO LTD (JP) 2014-04-16 EP disclosed
US-8436009-B2 Prodrug of triazolone compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-05-07 US disclosed
US-8436009-B2 Prodrug of triazolone compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-05-07 US disclosed
EP-2571862-A1 PRODRUG OF TRIAZOLONE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2013-03-27 EP disclosed
US-20130053563-A1 PRODRUG OF TRIAZOLONE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-02-28 US disclosed
US-20130053563-A1 PRODRUG OF TRIAZOLONE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-02-28 US disclosed
WO-2011145747-A1 PRODRUG OF TRIAZOLONE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-11-24 WO disclosed
WO-2011145747-A1 PRODRUG OF TRIAZOLONE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053563-A1 PRODRUG OF TRIAZOLONE COMPOUND F7, TFPI, TFPI2 ALDH1A1 1398/4885ERN1 2075/4885KDM4E 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.